Articles

Obicetrapib on Top of Maximally Tolerated Lipid-Modifying Therapies in Participants With or at High Risk for Atherosclerotic Cardiovascular Disease: Rationale and Designs of BROADWAY and BROOKLYN

Nicholls SJ, Nelson AJ, Ditmarsch M, et al.

First published: May 3, 2024  DOI: 10.1016/j.ahj.2024.05.002